Investigator
Unknown Institution
PPP2R1A mutations portend improved survival after cancer immunotherapy
Immune checkpoint blockade (ICB) therapy is effective against many cancers, although resistance remains a major issue and new strategies are needed to improve clinical outcomes
Ph.D
Chinese Academy of Sciences · Institute of Health Sciences
Bachelor of Science
East China Normal University · School of life science
US
Scopus: 35798492600
Researcher Id: H-6984-2019